S&P 500   5,123.41 (-1.46%)
DOW   37,983.24 (-1.24%)
QQQ   438.27 (-1.59%)
AAPL   176.55 (+0.86%)
MSFT   421.90 (-1.41%)
META   511.90 (-2.15%)
GOOGL   157.73 (-1.05%)
AMZN   186.13 (-1.54%)
TSLA   171.05 (-2.03%)
NVDA   881.86 (-2.68%)
AMD   163.28 (-4.23%)
NIO   4.11 (-7.85%)
BABA   71.29 (-4.76%)
T   16.31 (-0.67%)
F   12.61 (-3.30%)
MU   122.52 (-3.91%)
GE   154.63 (-1.93%)
CGC   7.80 (-4.29%)
DIS   114.01 (-2.68%)
AMC   2.65 (-5.36%)
PFE   25.86 (-1.82%)
PYPL   64.59 (-1.84%)
XOM   120.37 (-1.17%)
S&P 500   5,123.41 (-1.46%)
DOW   37,983.24 (-1.24%)
QQQ   438.27 (-1.59%)
AAPL   176.55 (+0.86%)
MSFT   421.90 (-1.41%)
META   511.90 (-2.15%)
GOOGL   157.73 (-1.05%)
AMZN   186.13 (-1.54%)
TSLA   171.05 (-2.03%)
NVDA   881.86 (-2.68%)
AMD   163.28 (-4.23%)
NIO   4.11 (-7.85%)
BABA   71.29 (-4.76%)
T   16.31 (-0.67%)
F   12.61 (-3.30%)
MU   122.52 (-3.91%)
GE   154.63 (-1.93%)
CGC   7.80 (-4.29%)
DIS   114.01 (-2.68%)
AMC   2.65 (-5.36%)
PFE   25.86 (-1.82%)
PYPL   64.59 (-1.84%)
XOM   120.37 (-1.17%)
S&P 500   5,123.41 (-1.46%)
DOW   37,983.24 (-1.24%)
QQQ   438.27 (-1.59%)
AAPL   176.55 (+0.86%)
MSFT   421.90 (-1.41%)
META   511.90 (-2.15%)
GOOGL   157.73 (-1.05%)
AMZN   186.13 (-1.54%)
TSLA   171.05 (-2.03%)
NVDA   881.86 (-2.68%)
AMD   163.28 (-4.23%)
NIO   4.11 (-7.85%)
BABA   71.29 (-4.76%)
T   16.31 (-0.67%)
F   12.61 (-3.30%)
MU   122.52 (-3.91%)
GE   154.63 (-1.93%)
CGC   7.80 (-4.29%)
DIS   114.01 (-2.68%)
AMC   2.65 (-5.36%)
PFE   25.86 (-1.82%)
PYPL   64.59 (-1.84%)
XOM   120.37 (-1.17%)
S&P 500   5,123.41 (-1.46%)
DOW   37,983.24 (-1.24%)
QQQ   438.27 (-1.59%)
AAPL   176.55 (+0.86%)
MSFT   421.90 (-1.41%)
META   511.90 (-2.15%)
GOOGL   157.73 (-1.05%)
AMZN   186.13 (-1.54%)
TSLA   171.05 (-2.03%)
NVDA   881.86 (-2.68%)
AMD   163.28 (-4.23%)
NIO   4.11 (-7.85%)
BABA   71.29 (-4.76%)
T   16.31 (-0.67%)
F   12.61 (-3.30%)
MU   122.52 (-3.91%)
GE   154.63 (-1.93%)
CGC   7.80 (-4.29%)
DIS   114.01 (-2.68%)
AMC   2.65 (-5.36%)
PFE   25.86 (-1.82%)
PYPL   64.59 (-1.84%)
XOM   120.37 (-1.17%)
NYSE:DGX

Quest Diagnostics (DGX) Stock Price, News & Analysis

$128.53
-1.49 (-1.15%)
(As of 04:28 PM ET)
Today's Range
$128.27
$130.30
50-Day Range
$123.78
$134.77
52-Week Range
$119.59
$148.62
Volume
717,994 shs
Average Volume
1.04 million shs
Market Capitalization
$14.27 billion
P/E Ratio
17.16
Dividend Yield
2.21%
Price Target
$144.18

Quest Diagnostics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.18 Rating Score
Upside/​Downside
12.2% Upside
$144.18 Price Target
Short Interest
Healthy
2.32% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.39mentions of Quest Diagnostics in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$1.91 M Sold Last Quarter
Proj. Earnings Growth
7.43%
From $8.75 to $9.40 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.88 out of 5 stars

Medical Sector

67th out of 2,784 stocks

Medical Laboratories Industry

1st out of 57 stocks

DGX stock logo

About Quest Diagnostics Stock (NYSE:DGX)

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

DGX Stock Price History

DGX Stock News Headlines

LifeMD Shares Come Back to Life on GLP-1 Business Growth (DGX)
LifeMD stock is surging as the company is riding the GLP-1 trend to double-digit revenue growth and projections for 67% earnings growth in 2024
The next Nvidia (and it’s not Microsoft or Facebook)
Imagine buying Bitcoin at $1,000. That would have been the trade of the decade... right? Well, I think there's an even bigger play to be made in the A.I. space.
Validea Detailed Fundamental Analysis - DGX
Quest Diagnostics (NYSE:DGX) Upgraded by StockNews.com to "Buy"
My Quest Story - Jessica Clow
The next Nvidia (and it’s not Microsoft or Facebook)
Imagine buying Bitcoin at $1,000. That would have been the trade of the decade... right? Well, I think there's an even bigger play to be made in the A.I. space.
My Quest Story - Pauline Chaves
She Is Not Skipping a Beat, and Patients Are Noticing
Key Takeaways From Quest Diagnostics Analyst Ratings
My Quest Story - Eddy Hurst
DGX Aug 2024 85.000 put
DGX Aug 2024 70.000 call
My Quest Story - Allan Mendez
Phlebotomist's Actions Keep One Patient Coming Back
See More Headlines
Receive DGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 1/31 Dividend
1/16/2024
Dividend Payable
1/31/2024
Last Earnings
2/01/2024
Ex-Dividend for 4/22 Dividend
4/05/2024
Today
4/12/2024
Dividend Payable
4/22/2024
Next Earnings (Confirmed)
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
Health Care Services
CUSIP
74834L10
Employees
48,000
Year Founded
1967

Price Target and Rating

Average Stock Price Target
$144.18
High Stock Price Target
$160.00
Low Stock Price Target
$130.00
Potential Upside/Downside
+11.7%
Consensus Rating
Hold
Rating Score (0-4)
2.18
Research Coverage
11 Analysts

Profitability

Net Income
$854 million
Pretax Margin
12.21%

Debt

Sales & Book Value

Annual Sales
$9.25 billion
Cash Flow
$12.50 per share
Book Value
$56.41 per share

Miscellaneous

Free Float
109,168,000
Market Cap
$14.34 billion
Optionable
Optionable
Beta
0.91

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

DGX Stock Analysis - Frequently Asked Questions

Should I buy or sell Quest Diagnostics stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last twelve months. There are currently 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DGX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DGX, but not buy additional shares or sell existing shares.
View DGX analyst ratings
or view top-rated stocks.

What is Quest Diagnostics' stock price target for 2024?

11 equities research analysts have issued 1 year price objectives for Quest Diagnostics' stock. Their DGX share price targets range from $130.00 to $160.00. On average, they anticipate the company's share price to reach $144.18 in the next year. This suggests a possible upside of 12.2% from the stock's current price.
View analysts price targets for DGX
or view top-rated stocks among Wall Street analysts.

How have DGX shares performed in 2024?

Quest Diagnostics' stock was trading at $137.88 at the beginning of the year. Since then, DGX shares have decreased by 6.8% and is now trading at $128.52.
View the best growth stocks for 2024 here
.

Are investors shorting Quest Diagnostics?

Quest Diagnostics saw a drop in short interest during the month of February. As of February 29th, there was short interest totaling 2,750,000 shares, a drop of 7.4% from the February 14th total of 2,970,000 shares. Based on an average trading volume of 1,040,000 shares, the short-interest ratio is currently 2.6 days. Approximately 2.5% of the shares of the company are sold short.
View Quest Diagnostics' Short Interest
.

When is Quest Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 23rd 2024.
View our DGX earnings forecast
.

How can I listen to Quest Diagnostics' earnings call?

Quest Diagnostics will be holding an earnings conference call on Tuesday, April 23rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 203-369-0197.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Incorporated (NYSE:DGX) issued its quarterly earnings results on Thursday, February, 1st. The medical research company reported $2.15 earnings per share for the quarter, beating the consensus estimate of $2.11 by $0.04. The medical research company had revenue of $2.29 billion for the quarter, compared to the consensus estimate of $2.25 billion. Quest Diagnostics had a net margin of 9.23% and a trailing twelve-month return on equity of 15.79%. The business's revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.98 earnings per share.
Read the conference call transcript
.

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics announced a quarterly dividend on Thursday, February 1st. Stockholders of record on Monday, April 8th will be paid a dividend of $0.75 per share on Monday, April 22nd. This represents a $3.00 dividend on an annualized basis and a dividend yield of 2.33%. The ex-dividend date of this dividend is Friday, April 5th. This is an increase from the stock's previous quarterly dividend of $0.71.
Read our dividend analysis for DGX
.

Is Quest Diagnostics a good dividend stock?

Quest Diagnostics (NYSE:DGX) pays an annual dividend of $2.84 per share and currently has a dividend yield of 2.16%. The company has been increasing its dividend for 13 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 37.92%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, DGX will have a dividend payout ratio of 30.21% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for DGX.

How will Quest Diagnostics' stock buyback program work?

Quest Diagnostics announced that its board has approved a share buyback plan on Thursday, February 2nd 2023, which authorizes the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 6% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board of directors believes its stock is undervalued.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics updated its FY24 earnings guidance on Thursday, February, 1st. The company provided EPS guidance of $8.60-8.90 for the period, compared to the consensus earnings per share estimate of $8.98. The company issued revenue guidance of $9.35-9.45 billion, compared to the consensus revenue estimate of $9.38 billion.

What is Steve Rusckowski's approval rating as Quest Diagnostics' CEO?

1,053 employees have rated Quest Diagnostics Chief Executive Officer Steve Rusckowski on Glassdoor.com. Steve Rusckowski has an approval rating of 78% among the company's employees.

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), Abbott Laboratories (ABT), NVIDIA (NVDA), Intel (INTC) and Cisco Systems (CSCO).

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by many different institutional and retail investors. Top institutional shareholders include International Assets Investment Management LLC (0.05%), Massmutual Trust Co. FSB ADV (0.02%), Banque Cantonale Vaudoise (0.02%), Czech National Bank (0.02%), CWM LLC (0.02%) and Somerset Trust Co (0.01%). Insiders that own company stock include Catherine T Doherty, Gail R Wilensky, Michael E Prevoznik, Michael J Deppe, Stephen H Rusckowski, Stephen H Rusckowski, Timothy M Ring and Vicky B Gregg.
View institutional ownership trends
.

How do I buy shares of Quest Diagnostics?

Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Quest Diagnostics have any subsidiaries?
The following companies are subsidiares of Quest Diagnostics: AmeriPath, AmeriPath Cincinnati Inc. (OH), AmeriPath Cleveland Inc. (OH), AmeriPath Consolidated Labs Inc. (FL), AmeriPath Florida LLC (DE), AmeriPath Hospital Services Florida LLC (DE), AmeriPath Inc. (DE), AmeriPath Indianapolis PC (IN), AmeriPath Kentucky Inc. (KY), AmeriPath Lubbock 5.01(A) Corporation (TX), AmeriPath New York LLC (DE), AmeriPath Texas Inc. (DE), AmeriPath Tucson Inc. (AZ), American Medical Laboratories, American Medical Laboratories Incorporated (DE), Associated Clinical Laboratories L.P. (PA), Associated Clinical Laboratories of Pennsylvania L.L.C. (PA), Athena Diagnostics, Athena Diagnostics Inc. (DE), Blueprint Genetics, Blueprint Genetics FZ-LLC (UAE), Blueprint Genetics Inc. (DE), Blueprint Genetics Oy (Finland), California Laboratory Associates, Cape Cod Healthcare - Business, Celera, ClearPoint Diagnostic, Clearpoint Diagnostic Laboratories LLC (TX), Cleveland HeartLab, Cleveland HeartLab Inc. (DE), Clinical Laboratory Partners, Colorado Pathology Consultants P.C. (CO), ConVerge Diagnostic Services, Consolidated DermPath Inc. (DE), DFW 5.01(a) Corporation (TX), DGXWMT JV LLC (DE), Dermatopathology of Wisconsin S.C. (WI), Diagnostic Laboratory of Oklahoma LLC (OK), Diagnostic Pathology Services Inc. (OK), Diagnostic Reference Services Inc. (MD), ExamOne Canada Inc. (New Brunswick), ExamOne LLC (DE), ExamOne World Wide Inc. (PA), ExamOne World Wide of NJ Inc. (NJ), Focus Diagnostics, HemoCue, Hoffman M.D. Associated Pathologists Chartered (NV), Institute for Dermatopathology Inc. (PA), Isabella Street Urban Renewal LLC (NJ), Kailash B. Sharma M.D. Inc. (GA), Kilpatrick Pathology P.A. (NC), LabOne, LabOne LLC (MO), LabOne of Ohio Inc. (DE), Laboratorio de Analisis Biomedicos S.A. (Mexico), Lancet Labs, MACL, Med Fusion LLC (TX), Med fusion, MedPlus, Mid America Clinical Laboratories LLC (IN), Nomad Massachusetts Inc. (MA), Nuclear Medicine and Pathology Associates (GA), Ocmulgee Medical Pathology Association Inc. (GA), Pathology Building Partnership (MD) (gen. ptnrshp.), PeaceHealth Laboratories, PhenoPath Laboratories, PhenoPath Laboratories PLLC (WA), Q Squared Solutions Holdings LLC (DE), Q Squared Solutions Holdings Limited (UK), Quest Diagnostics (Shanghai) Co. Ltd. (China), Quest Diagnostics Brasil Holdings Ltd. (UK), Quest Diagnostics Clinical Laboratories, Quest Diagnostics Clinical Laboratories Inc. (DE), Quest Diagnostics Domestic Holder LLC (DE), Quest Diagnostics HTAS India Private Limited (India), Quest Diagnostics Health & Wellness LLC (DE), Quest Diagnostics Holdings Incorporated (DE), Quest Diagnostics Holdings Ltd. (UK), Quest Diagnostics Incorporated (MD), Quest Diagnostics Incorporated (NV), Quest Diagnostics India Private Limited (India), Quest Diagnostics Infectious Disease Inc. (DE), Quest Diagnostics International Holdings Limited (UK), Quest Diagnostics International LLC (DE), Quest Diagnostics Investments LLC (DE), Quest Diagnostics Ireland Limited (Ireland), Quest Diagnostics LLC (CT), Quest Diagnostics LLC (IL), Quest Diagnostics LLC (MA), Quest Diagnostics Massachusetts LLC (MA), Quest Diagnostics Mexico Holding Company Trust (Mexico), Quest Diagnostics Mexico S de RL de CV (Mexico), Quest Diagnostics Nichols Institute (CA), Quest Diagnostics Nichols Institute Inc. (VA), Quest Diagnostics Receivables Inc. (DE), Quest Diagnostics Subsidiary Holdings Ltd. (UK), Quest Diagnostics TB LLC (DE), Quest Diagnostics Terracotta LLC (DE), Quest Diagnostics Venture LLC (PA), Quest Diagnostics Ventures LLC (DE), Quest Diagnostics do Brasil Ltda. (Brazil), Quest Diagnostics of Pennsylvania Inc. (DE), Quest Diagnostics of Puerto Rico Inc. (PR), Quest HealthConnect LLC (CA), ReproSource, Reprosource Fertility Diagnostics Inc. (MA), Solstas Lab Partners, Sonora Quest Laboratories LLC (AZ), Specialty Laboratories Inc. (CA), Summit Health, UMass Memorial Medical Center - Anatomic Pathology Outreach Laboratory Business, Unilab Corporation, and Unilab Corporation (DE).
Read More
This page (NYSE:DGX) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners